Survey of Global Investigative Sites, Provide Your Input Today
Survey of Global Investigative Sites
The Tufts Center for Drug Development is conducting a study in collaboration with Applied Clinical Trials to understand how the global site landscape is changing and what areas are most challenging to investigative sites. As clinical trials become increasingly more global, we are undertaking a survey to understand how globalization is affecting investigative sites.
We want to know investigator and study coordinator opinions and experiences for an article that will appear in our June 2010 issue. The more responses we receive the better, and your feedback is highly valued by sponsors. Sponsors will use the results of this survey to understand how they can better support your site, and others around the world.
Please take a moment to complete this important survey developed by the Tufts Center for the Study of Drug Development, and please forward this email to an investigator or site coordinator who might be interested.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
MariTide Shows Up to 20% Weight Loss in Phase II Trial for Obesity, Type 2 Diabetes
June 24th 2025In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained weight loss of up to 20% in adults with obesity, with or without type 2 diabetes, alongside notable improvements in glycemic control, supporting its advancement to Phase III studies as a potential once-monthly treatment option.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
